免疫细胞因子特征可预测接受溶瘤腺病毒 TILT-123 联合化疗及无 IL-2 过继性 TIL 治疗的晚期黑色素瘤患者的生存

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-fr

这些发现为 TILT-123 联合 TIL 疗法提供了机制上的见解，并为未来的生物标志物导向临床研究提出了方向。

实体瘤中的细胞治疗：我们准备好进入黄金时段了吗？

Cellular Therapies in Solid Tumors: Are We Ready for Primetime?

肉瘤细胞治疗：现状与未来方向

Cell therapy in sarcoma: current landscape and future directions.

实体瘤的免疫细胞治疗：当前挑战与治疗进展

Immune cell-based therapies for solid tumors, current challenges and therapeutic advances.

实体瘤的工程化免疫细胞治疗：药理学进展、临床结局与未来方向

Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions.

胃肠道肿瘤的细胞治疗：现状与未来方向

Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions.

白细胞介素-2 受体（IL-2R）激动剂在肿瘤免疫治疗中的现状与未来前景

Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy.

非血液系统实体瘤的过继性细胞疗法

Adoptive Cell Therapy for Nonhematologic Solid Tumors.

过继性 NK 细胞疗法：转移性黑色素瘤的有前景治疗方向

Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma.